Z
Zafrens
Unlocking value at the interface of biology, chemistry and engineering
About Zafrens
Zafrens is a biotechnology company focused on advancing cell biology through the development of high-resolution, high-throughput single-cell analysis platforms. By integrating microfluidics, photonics, and machine learning, Zafrens creates innovative tools that enable detailed insights into cellular behavior at scale. These tools are designed to accelerate drug discovery, cell therapy development, and other cutting-edge biomedical applications. The company’s proprietary technology enables researchers to capture and analyze complex biological data with unprecedented speed and accuracy, helping to answer critical questions in life sciences. Zafrens is driven by the goal of transforming how scientists understand and manipulate cells, paving the way for breakthroughs in personalized medicine and advanced therapeutic development.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- San Diego, United States
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 63.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, Techbio Drug Discovery, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Zafrens.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2025 | $8M | $115M | imec.xpand · Prime Movers Lab · Global Brain Corporation · KOFA Healthcare Investments | ↗ |
| EARLY VC✓Equity / VC | Dec 2023 | $23M | $92M | BlueYard Capital · KOFA Healthcare Investments · Prime Movers Lab · Possible Ventures | ↗ |
Growth signals
Latest recorded traffic for Zafrens is 580 monthly website visits, up 314.3% over the last three months. Zafrens's team declined 9.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
BlueYard Capital- KIKOFA Healthcare Investments
Prime Movers Lab
Possible Ventures
Global Brain Corporation
Alix Ventures
FoundersX Ventures
Hawktail- IVIaso Ventures
imec.xpand
Other known investors3 additional known investors
Chas Pulido
Helen Liang
Hexagon
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zafrens on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zafrens’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.